Targeted drug delivery enabled by genetically engineered nanoparticles
In a pre-clinical study, researchers were able to genetically engineer cell membrane-coated nanoparticles to deliver dexamethasone directly to the inflamed lungs of mice.
List view / Grid view
News
Global clinical trials market to value $77 billion by 2026
Market analysts suggest COVID-19 and the rising prevalence of chronic disease will both contribute to growth in the global clinical trials market.
![MBE Medals [Credit: HCSA (Health Care Supply Association)].](https://www.europeanpharmaceuticalreview.com/wp-content/uploads/MBE-300x278.png)
![MBE Medals [Credit: HCSA (Health Care Supply Association)].](https://www.europeanpharmaceuticalreview.com/wp-content/uploads/MBE.png)
MBE awarded to NICE’s Interventional Procedures Advisory Committee chairman
Professor Tom Clutton-Brock was awarded an MBE for his work in approving novel ventilators for the UK’s National Health Service during the COVID-19 pandemic.
Antibody cocktail improves survival in seronegative hospitalised COVID-19 patients
Phase III data shows REGEN-COV™ (casirivimab and imdevimab) reduced risk of death by 20 percent in hospitalised COVID-19 patients lacking an immune response to SARS-CoV-2.
CAR T therapy achieves high remission rate in acute lymphoblastic leukaemia trial
Trial data shows 71 percent of adult B cell acute lymphoblastic leukaemia patients receiving Tecartus® autologous anti-CD19-transduced CD3+ cell infusion achieved complete remission.
NVX-CoV2373 vaccine 90 percent effective in preventing symptomatic COVID-19
US trial results show NVX-CoV2373 was safe and effective in preventing symptomatic COVID-19, including in high-risk populations.
beti-cel gene therapy demonstrates durable efficacy in beta thalassaemia patients
The betibeglogene autotemcel (beti-cel) gene therapy caused paediatric and adult beta thalassaemia patients to achieve transfusion independence lasting over two years.
Alzheimer’s vaccine shows promise in Phase II trial
Study results show AADvac1, a first-in-man Alzheimer's disease tau vaccine, is safe and potentially of benefit for patients with mild disease.
Co-administration of flu and COVID-19 vaccines safe and effective
A trial comparing co-administration of influenza and COVID-19 vaccines to COVID-19 vaccine dosing alone found little effect on vaccine efficacy.
New consortium to develop PAT for cell and gene therapies
The Cell and Gene Therapy Catapult’s new consortium aims to accelerate therapeutic development by developing process analytical technologies (PAT) for cell and gene therapy manufacturing.
Health Canada to modernise its clinical trial regulations
Health Canada has proposed a single regulatory framework for clinical trials for all health products that will support innovation and streamline drug and medical device development.
G7 to share 870 million doses of COVID-19 vaccine with poorest countries
Global leaders at the G7 summit pledged 870 million COVID-19 vaccine doses, with half to be delivered by the end of 2021, to COVAX for distribution among low- and middle-income countries.
Pharmacovigilance Risk Assessment Committee meeting highlights, June 2021
The European Medicines Agency (EMA)’s drug safety committee (PRAC) concluded three safety signal reviews, two for COVID-19 interventions, at its June meeting.
Oxbryta® significantly improves haemoglobin levels in paediatric sickle cell disease patients
Data shows treating sickle cell disease patients aged four to 11 years with Oxbryta® (voxelotor) results in increases in haemoglobin associated with improved clinical status.
Janssen COVID-19 Vaccine – one regulator blocks use, another promotes it
EU recommends that batches of Janssen COVID-19 Vaccine not be released for use due to a cross contamination report, while the FDA authorises use of drug substance from the facility where the contamination occurred.
